T-Cell Immune Response Assessment as a Complement to Serology and Intranasal Protection Assays in Determining the Protective Immunity Induced by Acellular Pertussis Vaccines in Mice
Open Access
- 1 July 2003
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 10 (4) , 637-642
- https://doi.org/10.1128/cdli.10.4.637-642.2003
Abstract
The relative value of antibodies and/or T-cell immune responses to Bordetella pertussis antigens in the immunity induced by acellular pertussis (aP) vaccines is still an open issue, probably due to the incomplete knowledge on the mechanisms of protective immunity to pertussis. The relevance of T-cell immune responses in protection from pertussis has been demonstrated in murine and human models of infection; thus, in this study, the ability of different vaccine preparations of three component (pertussis toxin, filamentous hemagglutinin, and pertactin) aP vaccines to induce T-cell responses was investigated in mice. All vaccine preparations examined passed the immunogenicity control test, based on antibody titer assessment, according to European Pharmacopoeia standards, and protected mice from B. pertussis intranasal challenge, but not all preparations were able to prime T cells to pertussis toxin, the specific B. pertussis antigen. In particular, one vaccine preparation was unable to induce proliferation and gamma interferon (IFN-γ) production while the other two gave borderline results. The evaluation of T-cell responses to pertussis toxin antigen may provide information on the protective immunity induced by aP vaccines in animal models. Considering the critical role of the axis interleukin-12-IFN-γ for protection from pertussis, our results suggest that testing the induction of a key protective cytokine such as IFN-γ could be an additional tool for the evaluation of the immune response induced by aP vaccines.Keywords
This publication has 66 references indexed in Scilit:
- Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infectionFEMS Immunology & Medical Microbiology, 2002
- Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for considerationVaccine, 2001
- Protection againstBordetella pertussisin Mice in the Absence of Detectable Circulating Antibody: Implications for Long‐Term Immunity in ChildrenThe Journal of Infectious Diseases, 2000
- Acellular Vaccines Containing Reduced Quantities of Pertussis Antigens as a Booster in AdolescentsPediatrics, 1999
- Informal Consultation with Manufacturers and WHO Ad Hoc Working Group on Mouse Protection Models for Acellular Pertussis Vaccines National Institute for Biological Standards, 12 November 1998Biologicals, 1999
- Immunogenicity Issues in the Quality Control of the New Acellular Pertussis VaccinesBiologicals, 1999
- Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccinesVaccine, 1999
- Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T‐cell subsets as Th1, Th2 or Th0Immunology, 1996
- Defective response to T cell mitogens in mice injected with human immunodeficiency virus type 1-infected U937 cellsJournal of General Virology, 1994
- PLACEBO-CONTROLLED TRIAL OF TWO ACELLULAR PERTUSSIS VACCINES IN SWEDEN—PROTECIVE EFFICACY AND ADVERSE EVENTSThe Lancet, 1988